Erythrocyte CD38 as a prognostic marker in cancer

Abstract Background: Surface antigen CD38 which is a multifunctional protein with enzymatic and receptorial properties is involved in many processes of cell proliferation and activation. It is widely expressed within the hematopoetic system, and its expression is stimulated by proinflammatory cytokines. CD38-associated enzymatic activities in erythrocytes from cancer patients were investigated in this context. Methods: Erythrocyte NAD glycohydrolase and ADP-ribosyl cyclase activities in normal individuals and cancer patients were compared and correlation of these activities to CEA values and anemia were determined. Changes in CD38-expression were followed by SDS-PAGE and Western blot analysis of erythrocyte membrane proteins. Results: Erythrocyte NAD glycohydrolase and ADP-ribosyl cyclase activities were significantly increased in cancer, in parallel to enhancement of CD38 expression and in correlation with CEA values and anemia. Conclusions: An increased expression of CD38 which may be due to action of proinflammatory cytokines produced in tumor–host reactions appears to account for the elevations in erythrocyte CD38-associated enzyme activities in cancer patients. The changes in these enzyme activities may provide a prognostic outlook in view of their apparently close correlation to tumor progressions.

[1]  F. Malavasi,et al.  Human CD38, a cell‐surface protein with multiple functions , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Hyuntae Kim,et al.  Synthesis and degradation of cyclic ADP-ribose by NAD glycohydrolases. , 1993, Science.

[3]  B. Mroczko,et al.  Hematopoietic Growth Factors in Colorectal Cancer Patients , 2003, Clinical chemistry and laboratory medicine.

[4]  D. Teti,et al.  Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. , 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[5]  K. Shim,et al.  Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. , 1999, Cancer.

[6]  G. Wise,et al.  Cytokine variations in patients with hormone treated prostate cancer. , 2000, The Journal of urology.

[7]  Hyuntae Kim,et al.  NAD Glycohydrolases: A possible function in calcium homeostasis , 1994, Molecular and Cellular Biochemistry.

[8]  C. Rüegg.  Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions , 2006, Journal of Leukocyte Biology.

[9]  M. Yalcin,et al.  IL-8 in pleural effusion. , 1996, Respiratory medicine.

[10]  J. Berek,et al.  Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. , 1990, Cancer research.

[11]  T. Katada,et al.  NAD glycohydrolase specifically induced by retinoic acid in human leukemic HL-60 cells. Identification of the NAD glycohydrolase as leukocyte cell surface antigen CD38. , 1993, The Journal of biological chemistry.

[12]  J. Givel,et al.  Secretion of bioactive granulocyte-macrophage colony-stimulating factor by human colorectal carcinoma cells. , 1994, Cancer research.

[13]  Guo‐Jun Zhang,et al.  Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. , 1999, Anticancer research.

[14]  M. Ashburner.  A Laboratory manual , 1989 .

[15]  F. Malavasi,et al.  A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. , 1993, Biochemical and biophysical research communications.

[16]  B. Park,et al.  Function of NAD glycohydrolase in ADP-ribose uptake from NAD by human erythrocytes. , 1993, Biochimica et biophysica acta.

[17]  F. Malavasi,et al.  Human CD38: a glycoprotein in search of a function. , 1994, Immunology today.

[18]  K. Hedin.  Chemokines , 2002, International journal of gastrointestinal cancer.

[19]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[20]  G. Catalano,et al.  Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[21]  N. Solvason,et al.  Murine CD38: an immunoregulatory ectoenzyme. , 1995, Immunology today.

[22]  S. Deaglio,et al.  Human CD38: a (r)evolutionary story of enzymes and receptors. , 2001, Leukemia research.

[23]  J. Gershoni,et al.  Protein blotting: principles and applications. , 1983, Analytical biochemistry.

[24]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[25]  Y. G. Prall,et al.  Acetylcholinesterase: an enzymatic marker of human red blood cell aging. , 1998, Life sciences.

[26]  J. Bazan,et al.  Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. , 1993, Science.

[27]  S. Deaglio,et al.  CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, and IL-10 secretion in resting human monocytes. , 2002, Cellular immunology.

[28]  C. Peschle,et al.  Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. , 1995, British Journal of Cancer.

[29]  G. Kroemer,et al.  Erythrocytes: Death of a mummy , 2001, Cell Death and Differentiation.

[30]  E. Demiralp,et al.  Analysis of pleural effusions using flow cytometry. , 1996, Respiration; international review of thoracic diseases.

[31]  R. Graeff,et al.  Enzymatic synthesis and characterizations of cyclic GDP-ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity. , 1994, The Journal of biological chemistry.

[32]  P. Pekala,et al.  10 – Non-Oxidation–Reduction Reactions of Pyridine Nucleotides , 1982 .

[33]  E. Matutes,et al.  New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. , 2002, Journal of clinical pathology.

[34]  Ö. Demir,et al.  NAD Glycohydrolase Activities and ADP-Ribose Uptake in Erythrocytes From Normal Subjects and Cancer Patients , 2004, Bioscience reports.

[35]  J. Blay,et al.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. , 1992, Cancer research.

[36]  Stephen M Hewitt,et al.  The role of interleukin 1 in growth and metastasis of human cancer xenografts. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. Moss,et al.  ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins. , 1988, Advances in enzymology and related areas of molecular biology.

[38]  L. Yalcintepe,et al.  Hemin‐dependent induction and internalization of CD38 in K562 cells , 2003, Journal of cellular biochemistry.

[39]  N. Noguchi,et al.  Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. , 1993, The Journal of biological chemistry.

[40]  I. Pastan,et al.  Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. , 1990, Cancer research.

[41]  F. Malavasi,et al.  Post-translational Modification of CD38 Protein into a High Molecular Weight Form Alters Its Catalytic Properties* , 1996, The Journal of Biological Chemistry.

[42]  F. Schuber,et al.  Mechanism of Cyclization of Pyridine Nucleotides by Bovine Spleen NAD+ Glycohydrolase* , 1996, The Journal of Biological Chemistry.

[43]  D. Teti,et al.  Serum levels of interleukin 1β, interleukin 8 and tumour necrosis factor α as markers of gastric cancer , 2006 .

[44]  K. Syrigos,et al.  Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer , 2004, British Journal of Cancer.

[45]  P. Reitsma,et al.  Plasma cytokine and P‐selectin levels in advanced malignancy , 2005, Cancer.

[46]  B. Rollins,et al.  Inflammatory chemokines in cancer growth and progression. , 2006, European journal of cancer.